Here’s what you need to know:
1. Kovanaze was approved by the FDA in June 2016.
2. Unlike standard dental anesthetic, which is administered through needle injection, Kovanaze is administered through a nasal spray.
3. Kovanaze is a topic, tooth nerve anesthetic containing tetracaineHCl (an ester local anesthetic) and oxymetazolineHCl (a vasoconstrictor).
4. The anesthetic is meant for restoratives procedures on Teeth 4 through 13 and A through J in adults and children who weigh more than 40 kilograms.
5. St. Renatus announced the launch of Kovanaze at the 2016 American Dental Association Meeting.
More articles on anesthesia:
AAN inducts Dr. Joseph Pellegrini: 3 things to know
Anesthesia Business Consultants launches MACRA guidance platform: 3 notes
Does local anesthetic choice impact outpatient foot surgery cost? 3 study insights
